A clinical-stage biopharmaceutical company focused on developing innovative treatments for intracranial malignancies, including brain cancers such as glioblastoma and meningioma. The company's pipeline includes NEO100 and NEO212, candidates combining chemotherapeutic agents with natural compounds for oral administration.